Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine Results from a phase II, randomized, multicenter trial

Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine : Results from a phase II, randomized, multicenter trial

Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 169(2016) vom: 01. Aug., Seite 16-27
1. Verfasser: Leroux-Roels, Geert (VerfasserIn)
Weitere Verfasser: Marchant, Arnaud, Levy, Jack, Van Damme, Pierre, Schwarz, Tino F, Horsmans, Yves, Jilg, Wolfgang, Kremsner, Peter G, Haelterman, Edwige, Clément, Frédéric, Gabor, Julian J, Esen, Meral, Hens, Annick, Carletti, Isabelle, Fissette, Laurence, Tavares Da Silva, Fernanda, Burny, Wivine, Janssens, Michel, Moris, Philippe, Didierlaurent, Arnaud M, Van Der Most, Robbert, Garçon, Nathalie, Van Belle, Pascale, Van Mechelen, Marcelle
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2016
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Adaptive immune response Adjuvant system CD4(+) T cell Hepatitis B virus surface antigen Memory B cell mehr... Polyfunctionality Adjuvants, Immunologic Hepatitis B Antibodies Hepatitis B Surface Antigens Vaccines
LEADER 01000naa a22002652 4500
001 NLM260833193
003 DE-627
005 20231224194242.0
007 cr uuu---uuuuu
008 231224s2016 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2016.05.007  |2 doi 
028 5 2 |a pubmed24n0869.xml 
035 |a (DE-627)NLM260833193 
035 |a (NLM)27236001 
035 |a (PII)S1521-6616(16)30080-8 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Leroux-Roels, Geert  |e verfasserin  |4 aut 
245 1 0 |a Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine  |b Results from a phase II, randomized, multicenter trial 
264 1 |c 2016 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 31.03.2017 
500 |a Date Revised 13.08.2017 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. 
520 |a Immunogenicity and safety of different adjuvants combined with a model antigen (HBsAg) were compared. Healthy HBV-naïve adults were randomized to receive HBs adjuvanted with alum or Adjuvant Systems AS01B, AS01E, AS03A or AS04 at Days 0 and 30. Different frequencies of HBs-specific CD4+ T cells 14days post dose 2 but similar polyfunctionality profiles were induced by the different adjuvants with frequencies significantly higher in the AS01B and AS01E groups than in the other groups. Antibody concentrations 30days post-dose 2 were significantly higher in AS01B, AS01E and AS03A than in other groups. Limited correlations were observed between HBs-specific CD4+ T cell and antibody responses. Injection site pain was the most common solicited local symptom and was more frequent in AS groups than in alum group. Different adjuvants formulated with the same antigen induced different adaptive immune responses and reactogenicity patterns in healthy naïve adults. The results summary for this study (GSK study number 112115 - NCT# NCT00805389) is available on the GSK Clinical Study Register and can be accessed at www.gsk-clinicalstudyregister.com 
650 4 |a Clinical Trial, Phase II 
650 4 |a Journal Article 
650 4 |a Multicenter Study 
650 4 |a Randomized Controlled Trial 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Adaptive immune response 
650 4 |a Adjuvant system 
650 4 |a CD4(+) T cell 
650 4 |a Hepatitis B virus surface antigen 
650 4 |a Memory B cell 
650 4 |a Polyfunctionality 
650 7 |a Adjuvants, Immunologic  |2 NLM 
650 7 |a Hepatitis B Antibodies  |2 NLM 
650 7 |a Hepatitis B Surface Antigens  |2 NLM 
650 7 |a Vaccines  |2 NLM 
700 1 |a Marchant, Arnaud  |e verfasserin  |4 aut 
700 1 |a Levy, Jack  |e verfasserin  |4 aut 
700 1 |a Van Damme, Pierre  |e verfasserin  |4 aut 
700 1 |a Schwarz, Tino F  |e verfasserin  |4 aut 
700 1 |a Horsmans, Yves  |e verfasserin  |4 aut 
700 1 |a Jilg, Wolfgang  |e verfasserin  |4 aut 
700 1 |a Kremsner, Peter G  |e verfasserin  |4 aut 
700 1 |a Haelterman, Edwige  |e verfasserin  |4 aut 
700 1 |a Clément, Frédéric  |e verfasserin  |4 aut 
700 1 |a Gabor, Julian J  |e verfasserin  |4 aut 
700 1 |a Esen, Meral  |e verfasserin  |4 aut 
700 1 |a Hens, Annick  |e verfasserin  |4 aut 
700 1 |a Carletti, Isabelle  |e verfasserin  |4 aut 
700 1 |a Fissette, Laurence  |e verfasserin  |4 aut 
700 1 |a Tavares Da Silva, Fernanda  |e verfasserin  |4 aut 
700 1 |a Burny, Wivine  |e verfasserin  |4 aut 
700 1 |a Janssens, Michel  |e verfasserin  |4 aut 
700 1 |a Moris, Philippe  |e verfasserin  |4 aut 
700 1 |a Didierlaurent, Arnaud M  |e verfasserin  |4 aut 
700 1 |a Van Der Most, Robbert  |e verfasserin  |4 aut 
700 1 |a Garçon, Nathalie  |e verfasserin  |4 aut 
700 1 |a Van Belle, Pascale  |e verfasserin  |4 aut 
700 1 |a Van Mechelen, Marcelle  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 169(2016) vom: 01. Aug., Seite 16-27  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:169  |g year:2016  |g day:01  |g month:08  |g pages:16-27 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2016.05.007  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 169  |j 2016  |b 01  |c 08  |h 16-27